SYDNEY, Nov. 15, 2021 /PRNewswire/ -- The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), has announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test.
The results of the validation study, conducted at the Wyss Institute for Biologically Inspired Engineering at Harvard University, are a significant milestone for the Biosensor Platform and its advancement towards clinical trials.
Among the major findings it was reported:
- The SARS-CoV-2 Antibody biosensor assay was 100% sensitive and 100% specific using clinical COVID-19 positive and negative SARS CoV-2 human samples.
- The time in obtaining results was less than 10 minutes.
The study is the first step towards the validation of a rapid point-of-care diagnostic that LSBD intends to develop and commercialize for the quantitative measurement of antibodies against SARS-CoV-2 in saliva. The company will now work with Johns Hopkins University to commence clinical trials.
"We are very excited with the outcome of this program and are eager to validate the test in saliva. There is evidence in recent scientific literature correlating IgG, IgM responses to spike and receptor-binding domain (RBD) in the serum positively correlated with matched saliva samples." Chief Executive Officer and Chairman of The iQ Group Global, Dr. George Syrmalis said.
"This evidence confirms that serum and saliva IgG antibodies to SARS-CoV-2 are maintained in most COVID-19 patients for at least three months post symptom onset. Our objective is to deliver a SARS-CoV-2 test that is calibrated against the WHO reference preparation, non-invasive and easy to use by everyone."
"We anticipate three urgent applications for the technology including population screening; diagnosis as a complement to the RNA virus test for patients presenting late onset of symptoms; and post-vaccination screening to determine whether booster vaccines are required by assessing the degree of the antigen-specific antibody responses to a SARS-CoV-2 vaccine that's been administered."
About Life Science Biosensor Diagnostics Pty Ltd (LSBD)
Life Science Biosensor Diagnostics Pty Ltd (LSBD) is the company that owns and manages the intellectual property of the diagnostic Biosensor.
About The iQ Group Global Limited (NSX: IQG)
The iQ Group Global Ltd is a life science company that finds, funds and develops bioscience discoveries to create life-changing medical innovations.
About The iQ Group Global
The iQ Group Global is a group of companies that find, fund and develop bioscience discoveries to create life-changing medical innovations. Recognised by The Australian Financial Review for the second consecutive year as one of the country's Most Innovative Companies in 2020, The iQ Group Global's flagship innovations include the Biosensor Platform and TEX Core, a first-in-class oncology drug platform with the ability to develop a pipeline of novel oncology compounds. Visit our website: www.theiqgroupglobal.com
Media Contact:
James Gorman
+61 (0)2 8239 5400
james.gorman@theiqgroupglobal.com
View original content:https://www.prnewswire.com/news-releases/validation-study-showcases-success-of-lsbds-rapid-sars-cov-2-antibody-test-301423944.html
